The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! The stock increased 5.78% or $2.01 on November 23, hitting $36.79. About 1.22 million shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 145.43% since April 22, 2016 and is uptrending. It has outperformed by 140.02% the S&P500.
The move comes after 9 months positive chart setup for the $1.36 billion company. It was reported on Nov, 24 by Barchart.com. We have $39.00 PT which if reached, will make NASDAQ:CLVS worth $81.60M more.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on February, 23. They expect $-1.67 earnings per share, up 25.11% or $0.56 from last year’s $-2.23 per share. After $-1.70 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -1.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 9 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Clovis Oncology has been the topic of 24 analyst reports since September 10, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by SunTrust on Wednesday, August 24. The rating was maintained by Stifel Nicolaus on Friday, February 26 with “Buy”. Piper Jaffray maintained it with “Neutral” rating and $28 target price in Monday, November 16 report. On Friday, September 23 the stock rating was maintained by Suntrust Robinson with “Buy”. The firm has “Buy” rating given on Thursday, September 10 by WallachBeth Capital. As per Tuesday, November 17, the company rating was downgraded by Goldman Sachs. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Outperform” rating by Credit Suisse on Thursday, January 21. Chardan Capital Markets initiated the stock with “Sell” rating in Tuesday, October 25 report. Suntrust Robinson maintained the shares of CLVS in a report on Wednesday, August 24 with “Buy” rating. The firm has “Buy” rating given on Wednesday, September 21 by Stifel Nicolaus.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 2 in Q2 2016. Its up 1.00, from 1 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Meeder Asset Management Incorporated last reported 6,132 shares in the company. Barclays Public Ltd Liability last reported 24,178 shares in the company. Manufacturers Life Insurance Communication The has 0% invested in the company for 22,698 shares. Atwood And Palmer owns 100 shares or 0% of their US portfolio. Moreover, Rock Springs Lp has 0.13% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 125,000 shares. The New York-based Alliancebernstein Limited Partnership has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Victory Cap accumulated 0% or 161 shares. Northern Corporation holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 390,230 shares. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 678 shares in the company. Schwab Charles Investment Mgmt Incorporated reported 105,186 shares or 0% of all its holdings. The United Kingdom-based Old Mutual Global Invsts (Uk) Ltd has invested 0.02% in Clovis Oncology Inc (NASDAQ:CLVS). Citigroup accumulated 0% or 942 shares. Jpmorgan Chase Communications has 0% invested in the company for 79,299 shares. Bank Of America De, a North Carolina-based fund reported 7,240 shares. The New York-based Millennium Mngmt has invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS).
More news for Clovis Oncology Inc (NASDAQ:CLVS) were recently published by: Fool.com, which released: “Why Clovis Oncology Inc. Rose 52.7% in September” on October 10, 2016. Businesswire.com‘s article titled: “Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According …” and published on November 18, 2016 is yet another important article.
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.